Status: Recruiting
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer. To explore a new PD-1 inhibitor adjuvant chemotherapy model combined with radiotherapy to treat locally advanced rectal cancer.
Participants needed: 48
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Yong Zhang,MDUpdated: Oct 11, 2023Locations: 1
Eligibility criteria
Aged 18 to 70 years. [+7]
Patients have had or currently have other malignant tumors within 5 years. [+14]